Digoxin is associated with improved transplant-free interstage survival in high-risk but not low-risk patients with hypoplastic left heart syndrome (hlhs)

Tyler Brown,David Brown,James S. Tweddell,Katherine Bates,Carole Lannon,Jeffrey Anderson

Journal of the American College of Cardiology（2020）

引用 2|浏览27

暂无评分

摘要

Digoxin use has been associated with lower interstage mortality in infants with HLHS and variants. The NEONATE score was developed to risk stratify patients for interstage mortality or transplantation; risk factors included type of stage 1 palliation (S1P)—Norwood with BT or Sano shunt vs. Hybrid

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要